Skip to main content
BDSX logo

BDSX · Biodesix Inc · Investor Relations

Track BDSX — free
$22.34 +0.39 (+1.78%) Q2 2026 earnings call transcript
Market Cap
$231.60M
Shares
10.55M
Volume · Oct 28 55.2K Avg daily vol (3M) 102.43K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date Event Type
2026-11-05 21:30 UTC Biodesix Q3 2026 Earnings Conference Call Earnings call

Recent news

Date Headline
2026-10-22 Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026

LOUISVILLE, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30, 2026 after the close of trading on Thursday, November 5.

2026-10-19 American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification

New CHEST framework developed by a renowned multidisciplinary panel with expertise in building and managing lung nodule programs across diverse clinical practices LOUISVILLE, Colo., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc (NASDAQ: BDSX), a leader in diagnostic solutions, today announced

2026-10-19 Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers

Partnership with Vanderbilt University and Vanderbilt Health accelerates development of the first radiomics-based test for lung nodule risk assessment LOUISVILLE, Colo., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced the

2026-10-13 Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026

New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing LOUISVILLE, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced multiple presentations at CHEST 2026

2026-09-24 Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

Biodesix-led tumor-informed and tumor-naïve programs draw on the company’s bioinformatics and diagnostics test development expertise LOUISVILLE, Colo., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced strategic progress in

2026-09-14 Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings

Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules LOUISVILLE, Colo., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced

2026-09-03 Biodesix to Participate in Upcoming Investor Conferences

LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in three upcoming investor conferences: Lake Street Capital Markets’ 10 th Annual Best Ideas Growth

2026-08-05 Biodesix Announces Second Quarter 2026 Results and Highlights

Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in Q2 2026; Maintained FY 2026 Revenue Guidance of $108-114 million, mid-point reflects 25% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Aug.

2026-08-04 Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference

LOUISVILLE, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in a fireside chat and host in-person 1x1 investor meetings at Canaccord Genuity’s 46 th Annual

2026-07-22 Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026

LOUISVILLE, Colo., July 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, 2026 after the close of trading on Wednesday, August 5.

2026-05-21 Biodesix to Participate in Upcoming Investor Conferences

LOUISVILLE, Colo., May 21, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will participate in three upcoming investor conferences: Craig-Hallum 23 rd Annual Institutional Investor

2026-05-11 Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy

Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals LOUISVILLE, Colo., May 11, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that additional real-world clinical and economic data

2026-05-04 Biodesix Announces First Quarter 2026 Results and Highlights

Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in Q1 2026; Increased FY 2026 Revenue Guidance to $108-114 million, mid-point reflects 25% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., May 04, 2026 (GLOBE NEWSWIRE) --

2026-04-20 Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026

LOUISVILLE, Colo., April 20, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2026 after the close of trading on Monday, May 4.

2026-04-09 Biodesix Recognized as a Top Workplace for Third Consecutive Year

Employee-Driven, Prestigious National Recognition for the Consistently High-Performing Biodesix Culture LOUISVILLE, Colo., April 09, 2026 (GLOBE NEWSWIRE) -- Biodesix is proud to announce that it has earned the prestigious 2026 USA TODAY Top Workplaces award.

Past events

Date Event Type
2026-09-29 5th Annual Roth Healthcare Opportunities Conference Conference
2026-09-15 H.C. Wainwright 28th Annual Global Investment Conference Conference
2026-09-10 Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference Conference
2026-08-12 Canaccord Genuity’s 46th Annual Growth Conference Conference
2026-08-12 Canaccord Genuity's 46th Annual Growth Conference Conference
2026-08-05 Biodesix Q2 2026 Earnings Conference Call Earnings call
2026-06-24 TD Cowen Annual Tools/Dx Revolution Conference
2026-06-03 William Blair 46th Annual Growth Stock Conference Conference
2026-05-28 Craig-Hallum 23rd Annual Institutional Investor Conference Conference
2026-05-04 Biodesix Q1 2026 Earnings Conference Call Earnings call
2026-03-11 Barclays 28th Annual Global Healthcare Conference Conference
2026-03-03 TD Cowen's 46th Annual Health Care Conference Conference
2026-02-26 Biodesix Q4 2025 Earnings Conference Call Earnings call
2025-11-03 Biodesix Q3 2025 Earnings Conference Call Earnings call
2025-08-12 Canaccord Genuity 45th Annual Growth Conference Conference
2025-08-07 Biodesix Q2 2025 Earnings Conference Call Earnings call

Source: https://investors.biodesix.com/

Key facts CIK 1439725 CUSIP 09075X207 13F (30d) 3 filings 3 filers Visit website Investor relations